$145 Million is the total value of Asymmetry Capital Management, L.P.'s 30 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 72.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNC | New | CENTENE CORP | $11,996,000 | – | 164,489 | +100.0% | 8.25% | – |
| AZN | Sell | ASTRAZENECA PLC-SPONS ADRadr | $10,543,000 | -3.1% | 176,010 | -19.6% | 7.25% | +28.7% |
| SHC | Sell | SOTERA HEALTH CO | $10,209,000 | -12.5% | 421,341 | -9.8% | 7.02% | +16.3% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $9,701,000 | -14.3% | 142,246 | -12.8% | 6.67% | +13.9% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $9,365,000 | +125.3% | 57,979 | +139.0% | 6.44% | +199.4% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $9,362,000 | -23.2% | 52,702 | -28.9% | 6.44% | +2.1% |
| PODD | Sell | INSULET CORP | $7,945,000 | -29.5% | 28,943 | -33.0% | 5.46% | -6.3% |
| ALKS | New | ALKERMES PLC | $7,485,000 | – | 305,245 | +100.0% | 5.15% | – |
| ADPT | Sell | ADAPTIVE BIOTECHNOLOGIES | $6,872,000 | -40.6% | 168,172 | -41.5% | 4.72% | -21.1% |
| EPIX | Sell | ESSA PHARMA INC | $6,072,000 | -26.5% | 212,525 | -25.3% | 4.18% | -2.3% |
| KYMR | New | KYMERA THERAPEUTICS INC | $5,983,000 | – | 123,363 | +100.0% | 4.11% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $5,546,000 | – | 315,834 | +100.0% | 3.81% | – |
| MREO | Buy | MEREO BIOPHARMA GROUP PL-ADRadr | $5,130,000 | +43.2% | 1,618,328 | +52.2% | 3.53% | +90.3% |
| BDSX | Sell | BIODESIX INC | $5,038,000 | -44.1% | 381,378 | -14.1% | 3.46% | -25.7% |
| ASLN | Sell | ASLAN PHARMACEUTICALS LT-ADRadr | $3,940,000 | -13.0% | 1,194,070 | -11.7% | 2.71% | +15.6% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $3,477,000 | -10.5% | 101,776 | -13.8% | 2.39% | +18.9% |
| HOLX | New | HOLOGIC INC | $3,081,000 | – | 46,184 | +100.0% | 2.12% | – |
| GH | Sell | GUARDANT HEALTH INC | $3,036,000 | -67.9% | 24,443 | -60.5% | 2.09% | -57.3% |
| FOLD | New | AMICUS THERAPEUTICS INC | $2,885,000 | – | 299,284 | +100.0% | 1.98% | – |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCadr | $2,690,000 | -58.2% | 399,776 | -43.9% | 1.85% | -44.5% |
| ARGX | New | ARGENX SE - ADRadr | $2,440,000 | – | 8,104 | +100.0% | 1.68% | – |
| FBRX | Buy | FORTE BIOSCIENCES INC | $2,232,000 | +22.4% | 66,390 | +24.8% | 1.54% | +62.8% |
| BIO | New | BIO-RAD LABORATORIES-A | $1,919,000 | – | 2,979 | +100.0% | 1.32% | – |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $1,571,000 | -55.1% | 61,248 | -40.1% | 1.08% | -40.3% |
| GRPH | New | GRAPHITE BIO ORD | $1,568,000 | – | 51,039 | +100.0% | 1.08% | – |
| MCRB | New | SERES THERAPEUTICS INC | $1,509,000 | – | 63,259 | +100.0% | 1.04% | – |
| VERV | New | VERVE THERAPEUTICS ORD | $1,494,000 | – | 24,790 | +100.0% | 1.03% | – |
| RGLS | Sell | REGULUS THERAPEUTICS INC | $1,180,000 | -61.9% | 1,450,777 | -26.9% | 0.81% | -49.4% |
| BLSA | Buy | BCLS ACQUISITION CORP- CL A | $877,000 | +0.7% | 83,277 | +1.1% | 0.60% | +33.7% |
| GLTO | Sell | GALECTO INC | $308,000 | -55.4% | 60,968 | -46.3% | 0.21% | -40.6% |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -11,873 | -100.0% | -0.58% | – |
| SEEL | Exit | SEELOS THERAPEUTICS INC | $0 | – | -440,745 | -100.0% | -1.14% | – |
| RNLX | Exit | RENALYTIX AI PLC-ADRadr | $0 | – | -160,969 | -100.0% | -2.14% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -520,858 | -100.0% | -2.77% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -79,650 | -100.0% | -3.08% | – |
| RCUS | Exit | ARCUS BIOSCIENCES INC | $0 | – | -236,494 | -100.0% | -3.44% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -277,468 | -100.0% | -4.06% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -142,530 | -100.0% | -4.84% | – |
| UNH | Exit | UNITEDHEALTH GROUP INC | $0 | – | -29,357 | -100.0% | -5.65% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -53,855 | -100.0% | -5.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-07-28
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.